- Home
- XBIO vs QLGN Comparison
XBIO vs QLGN Comparison
Compare XBIO & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBIO
- QLGN
- Stock Information
- Founded
- XBIO N/A
- QLGN 1996
- Country
- XBIO United States
- QLGN United States
- Employees
- XBIO N/A
- QLGN N/A
- Industry
- XBIO Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- XBIO Health Care
- QLGN Health Care
- Exchange
- XBIO Nasdaq
- QLGN Nasdaq
- Market Cap
- XBIO 5.9M
- QLGN 5.8M
- IPO Year
- XBIO N/A
- QLGN N/A
- Fundamental
- Price
- XBIO $2.54
- QLGN $3.25
- Analyst Decision
- XBIO Hold
- QLGN
- Analyst Count
- XBIO 1
- QLGN 0
- Target Price
- XBIO N/A
- QLGN N/A
- AVG Volume (30 Days)
- XBIO 72.1K
- QLGN 3.5M
- Earning Date
- XBIO 11-13-2025
- QLGN 11-14-2025
- Dividend Yield
- XBIO N/A
- QLGN N/A
- EPS Growth
- XBIO N/A
- QLGN N/A
- EPS
- XBIO N/A
- QLGN N/A
- Revenue
- XBIO $2,858,935.00
- QLGN N/A
- Revenue This Year
- XBIO $1.99
- QLGN N/A
- Revenue Next Year
- XBIO $20.00
- QLGN N/A
- P/E Ratio
- XBIO N/A
- QLGN N/A
- Revenue Growth
- XBIO 13.30
- QLGN N/A
- 52 Week Low
- XBIO $2.20
- QLGN $1.61
- 52 Week High
- XBIO $13.93
- QLGN $8.81
- Technical
- Relative Strength Index (RSI)
- XBIO 38.98
- QLGN 52.42
- Support Level
- XBIO $2.51
- QLGN $2.36
- Resistance Level
- XBIO $2.70
- QLGN $2.85
- Average True Range (ATR)
- XBIO 0.20
- QLGN 0.29
- MACD
- XBIO -0.04
- QLGN 0.07
- Stochastic Oscillator
- XBIO 18.26
- QLGN 85.14
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.